Results 31 to 40 of about 235,116 (346)

Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells [PDF]

Cancer Science, 2005
Pancreatic ductal carcinoma (PDC) remains one of the most intractable human malignancies, mainly because of the lack of sensitive detection methods. Although gene expression profiling by DNA microarray analysis is a promising tool for the development of such detection systems, a simple comparison of pancreatic tissues may yield misleading data that ...
Madoka Ishikawa, Koji Yoshida, Y. Yamashita, J. Ota, S. Takada, Hiroyuki Kisanuki, Koji Koinuma, Y. L. Choi, R. Kaneda, T. Iwao, K. Tamada, K. Sugano, H. Mano   +12 more
semanticscholar   +3 more sources

Multidisciplinary Approach to a Patient with Acinar Cell Carcinoma, a Rare Pancreatic Malignancy

healthbook TIMES. Oncology Hematology, 2021
Acinar cell carcinoma (ACC) of the pancreas is a relatively rare malignant neoplasm that constitutes about 1% of all pancreatic exocrine tumors. The disease is generally managed similarly as pancreatic ductal adenocarcinoma (PDAC), with surgical ...
Maria Celeste Palmarocchi, Elisabetta Merlo, Marco Cefali, Sara De Dosso   +3 more
doaj   +2 more sources

Successful resection of port site recurrence of pancreatic ductal adenocarcinoma after laparoscopic distal pancreatectomy

Surgical Case Reports, 2023
Background There are many reports of port site recurrence after laparoscopic surgery for various types of cancer. However, only two cases of port site recurrence after laparoscopic pancreatectomy have been reported to date.
Takashi Aida, Ryota Iwase, Teruyuki Usuba, Yu Kumagai, Kenei Furukawa, Shinji Onda, Masaichi Ogawa, Toru Ikegami   +7 more
doaj   +1 more source

SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer [PDF]

, 2017
Pancreatic cancer has a devastating prognosis, with an overall 5-year survival rate of ~8%, restricted treatment options and characteristic molecular heterogeneity.
A H Allam, A Neesse, A Neesse, A V Biankin, A Xue, AB Seymour, AD Rhim, AK Witkiewicz, AM LeBeau, AR Shekouh, AV Biankin, B Hinz, BC Ozdemir, BJ Cochran, BJ Cochran, C Gaggioli, C Vennin, D Croucher, D Goldstein, D Herrmann, D Herrmann, D Mahadevan, D N Saunders, D Telgenhoff, DD Von Hoff, DR Croucher, DR Croucher, E Cerami, F Al-Ejeh, G Finak, H Shiomi, HW Smith, I Garrido-Laguna, J Condeelis, J Gao, J Gore, J Lee, J Li, J P Morton, J R W Conway, JA Lee, JJ Lee, JP Morton, K Kessenbrock, K L Vine, L Harris, M C Lucas, M J Cowley, M Nobis, M Pajic, M Pinese, M Ranson, MJ Duffy, ML Nyström, N L E Harris, N Waddell, P Bailey, P Carmeliet, P Timpson, P Timpson, R Cicchi, R F Shearer, R Kalluri, R Smith, RF Shearer, RG Rowe, RL Siegel, S Nurmenniemi, S Ulisse, SC Barry, SR Hingorani, SR Hingorani, TK Stutchbury, WA Schroder, Y Takeuchi, ZS Boyd, Ö Babur   +76 more
core   +1 more source

Mixed pancreatic acinar cell-ductal adenocarcinoma: Complexities in diagnosis and treatment

Current Problems in Cancer: Case Reports, 2022
Background: Acinar cell carcinoma of the pancreas (ACC) is a rare malignancy, accounting for approximately 1-2% of all pancreatic cancers. Up to a quarter of ACCs are estimated to contain a significant component of another histology such as ...
Abdullah Nasser, Catherine L. Forse, Cynthia Walsh, Terence Moyana, Rakesh Goel   +4 more
doaj   +1 more source

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma [PDF]

, 2016
Immunotherapy approaches for pancreatic ductal adenocarcinoma (PDAC) have met with limited success. It has been postulated that a low mutation load may lead to a paucity of T cells within the tumor microenvironment (TME).
Alvarez, Hector A., Bailey, Peter, Biankin, Andrew V., Chang, David K., Chattopadhyay, Chandrani, Ekmekcioglu, Suhendan, Forget, Marie-Andrée, Grimm, Elizabeth A., Haymaker, Cara, Hwu, Patrick, Kim, Sun-Hee, Maitra, Anirban, Roszik, Jason, San Lucas, Francis A.   +13 more
core   +1 more source

LIM only 4 is overexpressed in late stage pancreas cancer

Molecular Cancer, 2008
Background LIM-only 4 (LMO4), a member of the LIM-only (LMO) subfamily of LIM domain-containing transcription factors, was initially reported to have an oncogenic role in breast cancer.
Fujita Hayato, Cui Lin, Mizumoto Kazuhiro, Nakata Kohei, Ohuchida Kenoki, Yu Jun, Yamaguchi Hiroshi, Egami Takuya, Kitada Hidehisa, Tanaka Masao   +9 more
doaj   +1 more source

Pancreatic Acinar Cell Carcinoma in the Setting of a BRCA1 Germline Mutation

Annals of Internal Medicine: Clinical Cases, 2022
Pancreatic acinar cell carcinoma (PACC) is a rare neoplasm of the exocrine pancreas. PACC’s molecular and genetic features are poorly elucidated compared with pancreatic ductal cell carcinoma. Here, we present the patient case of a woman in her late 60s,
Leticia Campoverde, Monika Vyas, Andrea Bullock   +2 more
doaj   +1 more source

A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma [PDF]

, 2017
Aims: CDX2 is widely used as a sensitive and specific immunomarker for colorectal carcinoma (CRC) but neither this sensitivity nor specificity is absolute. This study is the first known comparison of CDX1 and A33 against CDX2 as immunomarkers for CRC.
Adamczyk, Lukasz A., Cullen, Jayne, Evans, Shanna, Oien, Karin A., Oniscu, Anca, Wong, Newton A.C.S.   +5 more
core   +1 more source

Targeting claudin‐4 enhances chemosensitivity of pancreatic ductal carcinomas [PDF]

Cancer Medicine, 2019
AbstractClaudin (CLDN) family comprises of protein that form a tight junction, and is involved in regulating polarity and differentiation of cells. Here, we aimed to investigate the effects of inhibiting CLDN4 in pancreatic ductal carcinomas (PDC).
Takamitsu Sasaki, Rina Fujiwara‐Tani, Shingo Kishi, Shiori Mori, Yi Luo, Hitoshi Ohmori, Isao Kawahara, Kei Goto, Yukiko Nishiguchi, Takuya Mori, Masayuki Sho, Masuo Kondo, Hiroki Kuniyasu   +12 more
openaire   +3 more sources